Nat. Med. 21 81–85 (2015); published online 22 December 2014; corrected after print 18 August 2016
In the version of this article initially published, the article did not mention some restrictions on the availability of reagents. The following text has been added to the HTML and PDF versions of the paper: “The retroviral vectors containing BCL-6 and BCL-xL have been generated by a for-profit company, AIMM Therapeutics, which makes the plasmids available. Obtaining the plasmids requires an MTA (http://www.aimmtherapeutics.com/partnering/academic-collaboration/) that includes financial obligations.” The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nm.3773
Rights and permissions
About this article
Cite this article
Linnemann, C., van Buuren, M., Bies, L. et al. Correction: Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 22, 1192 (2016). https://doi.org/10.1038/nm1016-1192d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1016-1192d
